Brief: Ajinomoto And Exelixis Enter Into A License Agreement To Discover And Develop Novel Antibody-Drug Conjugates For The Treatment Of Cancer

Ajinomoto Co

10/01/2023 13:30

Jan 10 (Reuters) - Ajinomoto Co Inc  2802.T :
    * AJINOMOTO AND EXELIXIS ENTER INTO A LICENSE AGREEMENT TO
DISCOVER AND DEVELOP NOVEL ANTIBODY-DRUG CONJUGATES FOR THE
TREATMENT OF CANCER
    * AJINOMOTO BIO PHARMA SERVICES - AS PART OF DEAL, EXELIXIS
WILL
HAVE RIGHT TO USE AJICAP TECHNOLOGY TO SUPPORT ITS AIM OF
ADVANCING MULTIPLE ADCS

Source text for Eikon:  ID:nPn6hP6Ypa 
Further company coverage:  2802.T 
 ((reuters.briefs@thomsonreuters.com;))